| 파이프라인 |
학회 |
발표제목 |
발표자료 |
| Nelmastobart (STT-003) |
SITC 2024 |
Spatial Biology Insights into Simultaneous Targeting of BTN1A1 and YAP in Cancer: Enhanced Efficacy in 3D Cultures and Clinical Trials 1 and 1b |
PDF
|
| Nelmastobart (STT-003) |
SITC 2024 |
First-in-Human Study of Nelmastobart(hSTC810), an Anti-BTN1A1 Antibody, in Advanced Solid Tumor Patients |
PDF
|
| Nelmastobart (STT-003) |
AACR 2024 |
BTN1A1 regulates T cell-mediated cancer immunotherapy by interacting with Galectin-9 |
PDF
|
| Nelmastobart (STT-003) |
AACR 2024 |
The effect of butyrophilin 1A1 (BTN1A1) blockade in combination with radiation treatment in tumor models |
PDF
|
| Nelmastobart (STT-003) |
SITC 2023 |
The effect of butyrophilin 1A1 (BTN1A1) blockade in combination with radiation treatment in tumor models |
PDF
|
| Nelmastobart (STT-003) |
SITC 2023 |
BTN1A1-Targeted Immunotherapy in combination with Standard of Care Therapy in Small Cell Lung and Colorectal Cancers |
PDF
|
| Nelmastobart (STT-003) |
2023 세계폐암학회(WCLC) |
Characterization of the Expression of BTN1A1 exclusive to PD-L1/PD-1 axis in Small Cell Lung Cancer using Spatial Biology Approach |
PDF
|
| Nelmastobart (STT-003) |
ASCO 2023 |
A phase I study of Nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors |
PDF
|
| Nelmastobart (STT-003) |
AACR 2023 |
Development of Diagnostic Antibodies For Anti-BTN1A1 Therapy, A Novel Immune Checkpoint Inhibitor Mutually Exclusive of PD-1/PD-L1 axis |
PDF
|
| Nelmastobart (STT-003) |
AACR 2023 |
Pharmacokinetic Analyses and Immunophenotyping of Patients Treated With Nelmastobart (hSTC810), A Novel Immune Checkpoint Inhibitor |
PDF
|
| Nelmastobart (STT-003) |
SITC 2022 |
A first-in human trial of hSTC810 (anti-BTN1A1 monoclonal antibody), targeting a novel immune checkpoint with a mutually exclusive expression with PD-1/PD-L1 in patients with relapsed/refractory solid tumors. (Journal for ImmunoTherapy of Cancer 2022;10(2 |
PDF
|
| Nelmastobart (STT-003) |
AACR 2022 |
Anti-BTN1A1 exhibits synergistic anti-tumor immunotherapeutic efficacy in combination with radiation therapy. (Cancer Res (2022) 82 (12_Supplement): 6321.) |
PDF
|
| Nelmastobart (STT-003) |
AACR 2022 |
Humanized STC10 is a monoclonal antibody to BTN1A1, a novel immunotherapeutic target to be evaluated in a planned phase 1 study. (Cancer Res (2022) 82 (12_Supplement): 5318.) |
PDF
|
| Nelmastobart (STT-003) |
SITC 2021 |
Targeting BTN1A1, an upstream regulator of PD-L1, as an alternative strategy in cancer immunotherapy |
PDF
|
| Nelmastobart (STT-003) |
AACR-NCI-EORTC 2021 |
The Immune Checkpoint Protein BTN1A1 Suppresses T Cell Activation through Interactions with Gal9 and PD-1 (Mol Cancer Ther (2021) 20 (12_Supplement): LBA019.) |
PDF
|
| Nelmastobart (STT-003) |
AACR 2021 |
BTN1A1: A Novel Immune Checkpoint for Cancer Immunotherapy Beyond The PD-1/PD-L1 Axis (Cancer Res (2021) 81 (13_Supplement): 1643.) |
PDF
|
| PD-1 (STT-002) |
AACR 2020 |
Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity (Cancer Res. 2020 Jun 1;80(11):2298-2310.) |
PDF
|
